Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Gugnani JS, Abhishek F, Agarwal Y, Damera AR, Kaur H, et al.
… systematic review article focuses on using rifabutin-based regimens as a treatment option after initial treatments have failed. The authors screened literature published in the last five years, between 2017 and 2022, across various search engines and closely examined relevant st…
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.
…ts with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed. Methods We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiori…
Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, et al.
…rtile range [IQR], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens were similar. Rates of acquired drug resistance were significantly higher among patients receiving delamanid versus bedaquiline (36% vs 10%, respectively; P Conclusions Among patients with MDR-TB, bedaquiline-ba…
Liu H, Zhu H, Fu L, Zhang W, Chen X, et al.
…ein synthesis inhibition, may undermine the efficacy of LZD regimens, and oxazolidinones with higher efficacy and lower toxicity during prolonged administration are needed. OTB-658 is an oxazolidinone anti-TB candidate derived from LZD that could replace LZD in TB treatment. We p…
Jihwaprani MC, Sun Y, Rizky WC, Sula I, Saquib N
…e aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceD…
Ivy Rukasha, Kabelo Gabriel Kaapu, Sarah M Fortune, Molebogeng Ruth Lekalakala-Mokaba
…ne (BDQ) has now become part of all standard drug-resistant regimens globally. However, emerging BDQ resistance is a growing worry, especially in areas with high rates of TB and HIV. This study aimed to compare BDQ-based regimens to non-BDQ-based treatments over a four-year perio…
Yan L, Kan X, Zhu L, Xu K, Yin J, et al.
Purpose We designed a prospective, multicenter, randomized, controlled study to assess a 5-month regimen compared with the standard regimen on previously treated patients with pulmonary tuberculosis (TB). Methods We enrolled 917 sputum smear-positive patients undergoing additiona…
Ira Shah, Dhruv N Gandhi, Ramsha Ansari, Himanshu Warse, Sachi Kalawadia, et al.
…BDQ)-based (without delamanid) antitubercular therapy (ATT) regimens in children aged 5-18 years. **METHODS:** A retrospective study was conducted between June 2021 and February 2024. We included 105 children diagnosed with drug-resistant tuberculosis (DR-TB) and treated with lo…
Aslan AF, Ortaköylü MG, Bağcı BA, Toprak S
…eatment.The aim of this study was to evaluate the treatment regimens and results of H-resistant pulmonary TB patients. Methods We retrospectively evaluated treatment regimens and results of 188 H-resistant pulmonary TB patients who were treated in our center between January 2015 …
Chang KC, Nuermberger E, Sotgiu G, Leung CC
Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public …
Agnarson AM, Wang XC, Potluri R, Bhandari H, Dhir A, et al.
…e high drug-resistant tuberculosis (DR-TB) burden in China. Regimens including the oral agent bedaquiline have been shown to be efficacious and safe, leading to its incorporation into multiple national TB treatment programs. This analysis evaluated the impact of increased adoptio…
Timothy M Walker, James A Watson, David A J Moore, Mike Frick, Euzebiusz Jamrozik
… designs have so far led to the implementation of effective regimens of 1-4 months' duration. Such regimens are a substantial improvement on the previous 6-9 months' duration standard of care but still far too long given potential toxicity and the very low baseline risk of diseas…
Fu L, Weng T, Sun F, Zhang P, Li H, et al.
…ive, and toxic treatment until short-course injectable-free regimens emerged. However, the new WHO-recommended regimens might be less feasible in the real-world setting. Here, we evaluated two optimized all-oral short-course regimens in China. Methods From April 2019 to August 20…
Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, et al.
There is urgent need for new drug regimens that more rapidly cure tuberculosis (TB). Existing TB drugs and regimens vary in treatment-shortening activity, but the molecular basis of these differences is unclear, and no existing assay directly quantifies the ability of a drug or r…
Bai-Yu Lee, Daniel L Clemens, Saša Masleša-Galic, Susana Nava, Chiao-Yueh Lo, et al.
We previously identified a potent 4-drug oral regimen comprising clofazimine, bedaquiline, pyrazinamide, and delamanid (parabolic response surface [PRS] regimen V) that dramatically shortens by approximately 85% the treatment duration needed to attain relapse-free cure of tubercu…
Anton C, Lemos CX, Machado FD, Bernardi RM, Freitas AA, et al.
…evaluate the association of use of alternative TB treatment regimens (without rifampicin and isoniazid) and mortality among patients requiring intensive care. Methods Retrospective cohort study, from January 2010 to December 2018. Patients aged > 18 years with a TB diagnosis, adm…
Nida Khan, Muhammad Ahmar Khan, Naila Muzaffar, Ahmad Ismail, Abdul Ghafoor, et al.
…according to the global estimates. Novel all oral treatment regimens containing new antibiotics with reduced treatment duration are available. World Health Organization guidelines recommend the use of shorter all-oral regimens under operational research. To guide recommendations,…
Pirmahmadzoda B, Hann K, Akopyan K, Grigoryan R, Geliukh E, et al.
…, and Tajikistan did so in 2013 and 2017. Novel and adapted regimens included individual regimens for RR/MDR, XDR (with and without Bedaquiline and Delamanid) and short treatment regimens with and without injectables. It is important to document the outcomes of the treatment regi…
Min J, Kim HW, Kang JY, Kim SK, Kim JW, et al.
…erculosis notified between 2011 and 2018 in Korea. Baseline regimens were classified into two groups, namely 6-9-month rifampicin, ethambutol, and pyrazinamide (6-9REZ) and a combination regimen of 2-month rifampicin, ethambutol, pyrazinamide and 7-10-month rifampicin and ethambu…
Aschmann HE, Musinguzi A, Musinguzi A, Kadota JL, Namale C, et al.
…le 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens. Methods From July to November 2022, we conducted a discrete choice experiment among adult PLHIV engaged in…
Zhang SJ, Yang Y, Sun WW, Zhang ZS, Xiao HP, et al.
…ess and safety of bedaquiline (BDQ)-containing and BDQ-free regimens for treatment of patients with refractory RR/MDR/XDR-TB. Methods Patients with refractory RR/MDR/XDR-TB receiving BDQ-containing regimens (BDQ group, n = 102) and BDQ-free regimens (non-BDQ group, n = 100) satis…
Kumar GS, Sameena P, Karthik V, Ghanate N
… treatment, and 40,397 (75%) were initiated on shorter drug regimens at the time of diagnosis. In the absence of an effective vaccine, there is an urgent need for new treatment regimens, drugs, and diagnostics to slow the evolution of drug resistance and limit transmission of res…
Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM
…randomization trial designs to select promising combination regimens in a platform adaptive trial. Methods Clinical trial simulation tools were built using predictive and validated parametric survival models of time to culture conversion (intermediate endpoint) and time to TB-rel…
van de Berg SEJ, Pelzer PT, van der Land AJ, Abdrakhmanova E, Ozi AM, et al.
…ernative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. …
Yihui Zhou, Hongxia Niu
… TB (RR-TB) posing critical challenges. Conventional longer regimens are characterized by suboptimal effectiveness, high toxicity, and poor tolerability. Consequently, there is an urgent demand for more effective, safer, shorter regimens with enhanced tolerability to replace trad…